An open-label, phase 2, multicenter study of the safety of long-term treatment with siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) in patients with multicentric castleman's disease

Authors
Category Systematic review
JournalBlood
Year 2013
This article has no abstract
Epistemonikos ID: 622809ff2265998bd60fbf7e666e41bba29de88a
First added on: Feb 05, 2025